Galectin Therapeutics (GALT) Return on Capital Employed (2011 - 2026)
Galectin Therapeutics' (GALT) quarterly Return on Capital Employed came in at 157.32% in Q1 2026, down 19912.0% year-on-year from N/an in Q1 2025, and up 36.02% quarter-over-quarter from 245.88% in Q4 2025.
Galectin Therapeutics (GALT) Return on Capital Employed (2011 - 2026) Analysis & Trends
Galectin Therapeutics' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 157.32% for Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 19912.0% year-over-year to 157.32% in Q1 2026; TTM through Mar 2026 was 157.32%, a 19912.0% decrease from a year earlier, with the FY2025 full-year figure at 191.59%, down 52939.0% from the prior year.
- Return on Capital Employed rose to 157.32% in Q1 2026 per GALT's latest filing, from 245.88% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 348.51% in Q4 2024 and bottomed at 1899.27% in Q2 2025.
- The 5-year median for Return on Capital Employed is 285.45% (2022), against an average of 382.77%.
- Biggest YoY gain for Return on Capital Employed was 131876 bps in 2025; the steepest drop was 157295 bps in 2025.
- Year by year, Return on Capital Employed stood at 582.19% in 2022, then jumped by 31 bps to 400.53% in 2023, then jumped by 187 bps to 348.51% in 2024, then sank by 171 bps to 245.88% in 2025, then jumped by 36 bps to 157.32% in 2026.
- Per Business Quant, the three latest GALT Return on Capital Employed figures stand at 157.32% (Q1 2026), 245.88% (Q4 2025), and 23.85% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Galectin Therapeutics | 227.21 Mn | 227.21 Mn | - | -157.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -157.32% |
| Dec 31, 2025 | -245.88% |
| Sep 30, 2025 | 23.85% |
| Jun 30, 2025 | -1,899.27% |
| Mar 31, 2025 | 41.80% |
| Dec 31, 2024 | 348.51% |
| Sep 30, 2024 | -1,294.91% |
| Jun 30, 2024 | -326.32% |
| Mar 31, 2024 | -259.35% |
| Dec 31, 2023 | -400.53% |
| Sep 30, 2023 | -369.28% |
| Jun 30, 2023 | -373.53% |
| Mar 31, 2023 | -420.29% |
| Dec 31, 2022 | -582.19% |
| Sep 30, 2022 | -285.45% |
| Jun 30, 2022 | -187.00% |
| Mar 31, 2022 | -119.91% |
| Dec 31, 2021 | -97.67% |
| Sep 30, 2021 | -111.54% |
| Jun 30, 2021 | -127.93% |